Q-omics provides the consensus-scored PIK3CD-AS2 profile across patient tissues and cancer cell-line models. PIK3CD-AS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PIK3CD-AS2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PIK3CD-AS2 RNA expression shows 17,498 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, KICH, and ACC as cancer lineages where PIK3CD-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3CD-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3CD-AS2 survival associations across molecular data types. PIK3CD-AS2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3CD-AS2 RNA expression–survival associations across cancer types. High PIK3CD-AS2 expression shows unfavorable associations in UCEC, ACC, LGG and SKCM, but favorable associations in LUAD and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PIK3CD-AS2 RNA expression.
This table summarizes PIK3CD-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PIK3CD-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3CD-AS2 shows lower tumor expression in KICH, UCEC, BRCA and THCA and higher tumor expression in LUAD and LUSC. The KICH box plot shows higher PIK3CD-AS2 RNA expression in normal versus tumor tissue (log2 FC = −2.944, t-test p < 0.001).
This table shows molecular features associated with PIK3CD-AS2 in patient tissues and cancer cell lines. In patient samples, PIK3CD-AS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
